<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Research Results in Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413 / 2313-8955-2014-1-1-48-52</article-id><article-id pub-id-type="publisher-id">230</article-id><article-categories><subj-group subj-group-type="heading"><subject>Archive categories</subject></subj-group></article-categories><title-group><article-title>PARALLELS OF LIPID METABOLISM AND HYPERHOMOCYSTEINEMIA IN PATIENTS WITH CORONARY HEART DISEASE AND METABOLIC SYNDROME</article-title><trans-title-group xml:lang="en"><trans-title>PARALLELS OF LIPID METABOLISM AND HYPERHOMOCYSTEINEMIA IN PATIENTS WITH CORONARY HEART DISEASE AND METABOLIC SYNDROME</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Efremova</surname><given-names>Olga A.</given-names></name><name xml:lang="en"><surname>Efremova</surname><given-names>Olga A.</given-names></name></name-alternatives><email>efremova@bsu.edu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Kamyshnikova</surname><given-names>Lyudmila A.</given-names></name><name xml:lang="en"><surname>Kamyshnikova</surname><given-names>Lyudmila A.</given-names></name></name-alternatives><email>kamyshnikova@bsu.edu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Nikitin</surname><given-names>Valeriy M.</given-names></name><name xml:lang="en"><surname>Nikitin</surname><given-names>Valeriy M.</given-names></name></name-alternatives><email>nikitin@bsu.edu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Lipunova</surname><given-names>Elena A.</given-names></name><name xml:lang="en"><surname>Lipunova</surname><given-names>Elena A.</given-names></name></name-alternatives><email>lipunova@bsu.edu.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2014</year></pub-date><volume>1</volume><issue>1</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2014/1/selection_8.pdf" /><abstract xml:lang="ru"><p>The article provides the analysis of cholesterol spectrum indices, homocysteine levels, and vascular wall rigidity in 120 patients of the cardiology department. The authors have revealed abnormalities of lipid spectrum of blood serum leading to hypertriglyceridemia, the increase in low density lipoprotein (LDLP) cholesterol, and decrease in high density lipoproteins (HDLP). The article demonstrates the clinical and pathogenic relationship of lipid profile with pro-inflammatory factors in patients with metabolic syndrome (MS) and coronary artery disease (CAD), as well as the interrelation of hyperhomocysteinemia (HHC) and LDL cholesterol. Since the progression of MS and CAD is associated with the development of endotheliosis, it is possible that the increase in systemic inflammation factors and development provokes HHC, i.e., effects on the inflammatory process are likely to have a corrective impact on HHC. Therefore, the study once again confirms the fact that MS identifies markers of chronic inflammation compared to the other so-called traditional risk factors of cardiovascular disease. The increased non- HDLP cholesterol level, as well as the activity of nonspecific inflammation in MS, may serve a poor prognostic marker of cardiovascular disorders.</p></abstract><trans-abstract xml:lang="en"><p>The article provides the analysis of cholesterol spectrum indices, homocysteine levels, and vascular wall rigidity in 120 patients of the cardiology department. The authors have revealed abnormalities of lipid spectrum of blood serum leading to hypertriglyceridemia, the increase in low density lipoprotein (LDLP) cholesterol, and decrease in high density lipoproteins (HDLP). The article demonstrates the clinical and pathogenic relationship of lipid profile with pro-inflammatory factors in patients with metabolic syndrome (MS) and coronary artery disease (CAD), as well as the interrelation of hyperhomocysteinemia (HHC) and LDL cholesterol. Since the progression of MS and CAD is associated with the development of endotheliosis, it is possible that the increase in systemic inflammation factors and development provokes HHC, i.e., effects on the inflammatory process are likely to have a corrective impact on HHC. Therefore, the study once again confirms the fact that MS identifies markers of chronic inflammation compared to the other so-called traditional risk factors of cardiovascular disease. The increased non- HDLP cholesterol level, as well as the activity of nonspecific inflammation in MS, may serve a poor prognostic marker of cardiovascular disorders.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>coronary heart disease</kwd><kwd>metabolic syndrome</kwd><kwd>diagnosis</kwd><kwd>lipid profile</kwd><kwd>homocysteine</kwd></kwd-group><kwd-group xml:lang="en"><kwd>coronary heart disease</kwd><kwd>metabolic syndrome</kwd><kwd>diagnosis</kwd><kwd>lipid profile</kwd><kwd>homocysteine</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>1. &amp;nbsp; Reaven G.M. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease // Circulation. 2002. № 106.P. 286-288.</mixed-citation></ref><ref id="B2"><mixed-citation>2.&amp;nbsp;&amp;nbsp; Efremova, O.A., Nikitin V.M., Lipunova E.A., Anohin D.A., Kamyshnikova L.A. Estimate or the Effectiveness of Intelligent Information System of Early Diagnosis and Prognosis of Cardiovascular Disease // World Applied Sciences Journal. 2013. № 26 (9). P 1204-1208.</mixed-citation></ref><ref id="B3"><mixed-citation>3.&amp;nbsp;&amp;nbsp; Grundy S.M., Cleeman J.I., Merz C. N.B., Brewer H.B., Jr; Clark L.T., Hunninghake D.B., et al. For the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. NCEP Report // Circulation. 2004. №110. P. 227-239.</mixed-citation></ref><ref id="B4"><mixed-citation>4.&amp;nbsp;&amp;nbsp; Grundy MA, Sempos CT, Grundy SM. Excess body weight. An under&amp;ndash;recognized contributor to dyslipidemia in white American women // Arch. Intern.Med. 1994. 154. P. 401&amp;ndash;410.</mixed-citation></ref></ref-list></back></article>